Cargando…
B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
Autores principales: | Musto, P., Minnema, M.C., Roeloffzen, W.W.H., Capra, A., van der Holt, B., Juul Vangsted, A., Broyl, A., Schjesvold, F., Lund, T., Silkjaer, T., Benjamin, R., Grasso, M., Lung Wu, K., Caers, J., Cavo, M., Hájek, R., Bruno, B., Gadisseur, A., Pietrantuono, G., Offidani, M., Pour, L., Sonneveld, P., Boccadoro, M., van de Donk, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171700/ http://dx.doi.org/10.1097/01.HS9.0000936104.91195.3e |
Ejemplares similares
-
B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
por: van de Donk, N., et al.
Publicado: (2023) -
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021) -
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2023) -
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020) -
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)